Table 1.
In the table below are listed the main PLP inhibitors reported in this review.
| Class | Lead Compound(s) | Target Molecule | Drug Development Stage |
|---|---|---|---|
| Tribulus terrestris derivates [71] | Terrestrimine | SARS-CoV PLP | Preclinical |
| Angelica keiskei derivates [72] | Xanthoangelol E | SARS-CoV 3CLP and PLP-whole enzymatic activity | Preclinical |
| Broussonetia Papyrifera derivates [73] | Papyriflavonol A | SARS and MERS-CoV 3CL and whole PLP | Preclinical |
| Psoralea Corylifolia derivates [74] | Isobavachalcone | SARS-CoV PLP | Preclinical |
| Psoralidin | |||
| Strobilanthes cusia derivates [75] | Tryptanthrin | hCoV-NL63 (PLP2-proposed) | Preclinical |
| Indigodole B | |||
| Thiopurine analogs [76,77] | 6-Thioguanine | SARS-CoV PLP protease and MERS-CoV PLP protease and DUB | Clinically used |
| 6-Mercaptopurine | |||
| Acethaldeyde dehydrogenase inhibitor [78] | Disulfiram | SARS and MERS-CoV PLPs | Clinically used |
| Endogenous peptide [79] | Cystatin C | Human coronaviruses OC43 and 229e (PLPs proposed) | Endogenous Peptide |